← back to search

Emily Prendergast

Minnesota Oncology · US
Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, and Cancer Genomics and Diagnostics.
h-index
13
citations
885
works
70
NIH funding
primary concept
Medicine
email

Recent publications

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology 2025cited by 29position: middledoi
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Journal of Clinical Oncology 2023cited by 36position: middledoi
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial
Cancer 2023cited by 22position: middledoi
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report
Gynecologic Oncology 2023cited by 20position: middledoi
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Journal of Clinical Oncology 2022cited by 372position: middledoi
Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Journal of Clinical Oncology 2020cited by 23position: middledoi
Social needs in gynecologic oncology: A Society of Gynecologic Oncology (SGO) clinical practice statement
Gynecologic Oncology 2020cited by 8position: middledoi
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort
Gynecologic Oncology 2016cited by 43position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Bradley J. Monk · University of Cincinnati Medical Center4 papers (2020–2025)David M. O’Malley · Bexley Hall4 papers (2020–2025)Peter G. Rose · Roswell Park Comprehensive Cancer Center3 papers (2020–2023)Kathleen N. Moore · Oklahoma City University3 papers (2016–2025)Mansoor Raza Mirza · C4 Therapeutics (United States)2 papers (2020–2023)Divya Gupta · Emory Healthcare2 papers (2020–2023)Nicoletta Colombo · University of Milan2 papers (2023–2025)Whitney A. Spannuth Graybill · University of Charleston2 papers (2020–2023)Hye Sook Chon · Moffitt Cancer Center2 papers (2023–2025)Philippe Follana · Université Claude Bernard Lyon 12 papers (2020–2023) · 2 papers (2020–2023)E. Salinas · University of Iowa2 papers (2023–2025) · 2 papers (2020–2023) · 2 papers (2023–2025)Antonio González-Martı́n · Opexa Therapeutics (United States)2 papers (2020–2023)Hannelore Denys · ZNA Middelheim Hospital2 papers (2020–2023)Alessandro D. Santin · Yale University2 papers (2023–2025)Lydia Gaba · Breast Cancer Research Foundation2 papers (2020–2023) · 2 papers (2020–2023)Jean‐François Baurain · Cliniques Universitaires Saint-Luc2 papers (2020–2023)